---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107389"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:23:32.225991+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium Q3 revenue $209.4M (+31% YoY); raises 2025 guidance

## Summary
- GAAP net income $31.5M ($0.84 diluted EPS); adj. net income $87.3M ($2.25 adj. EPS).
- Record Jornay PM revenue $41.8M; prescriptions up 20% YoY; pain portfolio $167.6M (+11%).
- Full-year 2025 revenue guidance raised to $775-785M; adj. EBITDA guidance $460-470M.
- Ended Q3 with $285.9M cash; Board authorized $150M share repurchase through Dec 2026.
- Adjusted EBITDA $133.0M, up 27% YoY; generated $78.4M cash from operations.

## SEC filing metadata
- accession: 0001104659-25-107389
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/0001104659-25-107389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/coll-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107389
- JSON: https://secwatch.observer/filing/0001104659-25-107389.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.